Internal Medicine Department, Vila Nova de Gaia/Espinho Hospital Center, E.P.E., Vila Nova de Gaia, Portugal.
Internal Medicine Department, Vila Nova de Gaia/Espinho Hospital Center, E.P.E., Vila Nova de Gaia, Portugal.
J Am Med Dir Assoc. 2020 Apr;21(4):481-485. doi: 10.1016/j.jamda.2019.12.018. Epub 2020 Jan 23.
Anticholinergic drugs have several side effects, and they have been associated with adverse outcomes, particularly in older patients. The aim of this study was to analyze anticholinergic burden and its relationship to delirium and mortality in older acutely ill medical patients.
Cohort study.
Patients 65 years of age and older who were admitted to an Internal Medicine ward between August 1 and December 31, 2016.
Anticholinergic drug use, outpatient and inpatient, was assessed using the Anticholinergic Cognitive Burden Scale (ACB). Prevalent delirium was diagnosed by the Short Confusion Assessment Method (Short-CAM).
Of the 198 patients, 28.3% developed delirium. Mortality rate was 13.6% in-hospital and 45.6% at 12 months. In multivariate analysis, outpatient ACB was associated with delirium, with an odds ratio (OR) of 1.65 [95% confidence interval (CI) 1.09-2.51]. Those with delirium had longer hospital stays (median 13 vs 8 days; P = .01), received more drugs (median 18 vs 15; P = .02), and presented a higher inpatient ACB (mean 3.9 vs 3.1; P = .034). No increased risk was found for in-hospital or 12-month mortality with drug use, ACB, or delirium.
In the population studied, we found an association between anticholinergic burden as measured by the ACB and the presence of delirium, but not with mortality at 12 months. A very high 12-month mortality rate might have been an obstacle for association recognition.
Clinician awareness of possible drug side effects, especially in older populations, is crucial. As part of medication reconciliation at the time of hospitalization, ACB of prehospitalization medications should be routinely calculated by inpatient pharmacy services and made available to medical teams.
抗胆碱能药物有多种副作用,并与不良结局相关,尤其是在老年患者中。本研究旨在分析老年急性内科住院患者的抗胆碱能药物负担及其与谵妄和死亡率的关系。
队列研究。
2016 年 8 月 1 日至 12 月 31 日期间入住内科病房的 65 岁及以上患者。
使用抗胆碱能认知负担量表(ACB)评估门诊和住院患者的抗胆碱能药物使用情况。采用简短的意识模糊评估方法(Short-CAM)诊断现患谵妄。
198 例患者中,28.3%发生谵妄。住院期间死亡率为 13.6%,12 个月时死亡率为 45.6%。多变量分析显示,门诊 ACB 与谵妄相关,比值比(OR)为 1.65(95%置信区间[CI]:1.09-2.51)。发生谵妄的患者住院时间更长(中位数 13 天 vs 8 天;P =.01),接受的药物更多(中位数 18 种 vs 15 种;P =.02),住院 ACB 更高(平均 3.9 分 vs 3.1 分;P =.034)。药物使用、ACB 或谵妄与住院期间或 12 个月死亡率无增加风险相关。
在本研究人群中,我们发现 ACB 测量的抗胆碱能药物负担与谵妄之间存在关联,但与 12 个月死亡率无关。非常高的 12 个月死亡率可能是识别关联的障碍。
临床医生对可能的药物副作用的认识至关重要,尤其是在老年人群中。作为住院期间药物调整的一部分,住院药房服务应常规计算住院前药物的 ACB,并提供给医疗团队。